Based on the bone-anabolic effects of PKG2, we hypothesized that pharmacological or genetic PKG2 activation may prevent GIOP, and we tested this hypothesis in a dexamethasone-induced (Dx-induced) osteoporosis model in male C57BL/6NHsd mice. The gene discussed is PRKG2; the disease is osteoporosis.